Determination of Ganciclovir and its prodrug Valganciclovir by hydrophilic interaction liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 5-6, 2011, Pages 436-442

  Heinig, Katja ^a   Wirz, Thomas ^a   Gajate Perez, Almudena ^a   Belli, Sara ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Dried blood spots (DBS) ; Ganciclovir (GCV); Hydrophilic interaction liquid chromatography (HILIC); Liquid chromatography tandem mass spectrometry (LC MS MS); Plasma; Valcyte ; Valganciclovir (VGC)

Indexed keywords

DRIED BLOOD SPOTS; GANCICLOVIR (GCV); HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHY (HILIC); LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS); VALGANCICLOVIR (VGC);

ACETONITRILE; BLOOD; COLUMN CHROMATOGRAPHY; DEUTERIUM; ELECTROSPRAY IONIZATION; ESTERS; HYDROPHILICITY; IONIC LIQUIDS; MASS SPECTROMETRY; PLASMA (HUMAN); PLASMAS; SILICA;

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

GANCICLOVIR; VALGANCICLOVIR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BLOOD SPECIMEN COLLECTION; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; GANCICLOVIR; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

RATTUS;

EID: 79451473451     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.12.033     Document Type: Article

References (22)

1. Martin D.F., Sierra-Madero J., Walmsley S., et al. N. Engl. J. Med. 2002, 346:1119-1126.
2. Paya C., Humar A., Dominguez E., et al. Am. J. Transplant. 2004, 4:611-620.
3. Maag H. Prodrugs: Challenges and Rewards Part 1. Biotechnology: Pharmaceutical Aspects 2007, Springer, New York.
4. Espinosa Bosch M., Ruiz Sánchez A.J., Sánchez Rojas F., Bosch Ojeda C. Asian J. Pharm. Sci. 2009, 4:254-264.
5. Chu F., Kiang C.-H., Sung M.-L., Huang B., Reeve R.L., Tarnowski T. J. Pharm. Biomed. Anal. 1999, 21:657-667.
6. Chan R., LaFargue J., Reeve R.L., Tam Y., Tarnowski T. J. Pharm. Biomed. Anal. 1999, 21:647-656.
7. Burri M., Wiltshire H., Kahlert C., Wouters G., Rudin C. Pediatr. Infect. Dis. J. 2004, 23:263-266.
8. Acosta E.P., Brundage R.C., King J.R., et al. Clin. Pharm. Therap. 2007, 81:867-872.
9. Xu H.-R., Li X.-N., Chen W.-L., Liu G.-Y., Chu N.-N., Yu C. J. Chromatogr. B 2007, 848:329-334.
10. Yadava M., Upadhyay V., Singhal P., Goswami S., Shrivastav P.S. J. Chromatogr. B 2009, 877:680-688.
11. Kasiari M., Gikas E., Georgakakou S., Kazanis M., Panderi I. J. Chromatogr. B 2008, 864:78.
12. Brown S.D., White C.A., Bartlett M.G. Rapid Commun. Mass Spectrom. 2002, 16:1871.
13. FDA Guidance for Industry, Bioanalytical Method Validation, May 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory%20Information/Guidances/ucm070107.pdf.
14. EMA draft Guideline on Validation of Bioanalytical Methods, Nov 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500018062.pdf.
15. Timm U., Wall M., Dell D. J. Pharm. Sci. 1985, 74:972-977.
16. ToxKin™, Version 3.5.3, Entimo AG, 2008.
17. Xu R.N., Rieser M.J., El-Shourbagy T.A. Bioanalysis 2009, 1:239-253.
18. Van Eeckhaut A., Lanckmans K., Sarre S., Smolders I., Michotte Y. J. Chromatogr. B 2009, 877:2198-2207.
19. Li W., Tse F.L.S. Biomed. Chromatogr. 2010, 24:49-65.
20. Keevil B.G. Clin. Biochem. 2011, 44:110-118.
21. Brown F., Banken L., Saywell K., Arum I. Clin. Pharmacokinet. 1999, 37:167-176.
22. Rowland M., Emmons G.T. AAPS J. 2010, 12:290-293.